However, when you buy something through our retail links, Condé Nast may earn an affiliate commission.If you’re looking for a reason to forgo foundation, good news: The best tinted moisturizers for ...

Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. | Having recently trimmed back its pipeline to a sole cancer candidate, ...

Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including ...

If you want a top-notch laptop with serious gaming chops, then you need to jump on this HP Omen 17 deal at B&H. It normally ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

It's probably worth relying on the recent Musselburgh winner King Ulanda in the handicap hurdle for conditional jockeys (2.50 ...

The FDA has granted PYX-201 fast track designation for treatment of recurrent or metastatic HNSCC after progression post-chemoimmunotherapy. PYX-201 received FDA fast track designation for use in ...

A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC), PYX-201, to treat adults with recurrent or metastatic head and neck ...

PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma. The FDA granted fast track designation to PYX-201 for the treatment of adult patients ...